The results showed that there were trends linking these cytokines, CCL20, CXCL1, CXCL2, CXCL5, and CXCL16, to ADO expression in gliomas but these correlations were not significant, probably due to the low number of patients recruited to the study (Fig. 5d; Supplementary Table 3). This evidence concerns the gene ADO and central nervous system cancer.